| Literature DB >> 35898892 |
Xiaolu Shi1, Ye Tian1, Yang Liu1, Zhengrong Xiong2,3, Shaobo Zhai1, Shunli Chu1, Fengxiang Gao2,3.
Abstract
The aggressive growth of cancer cells brings extreme challenges to cancer therapy while triggering the exploration of the application of multimodal therapy methods. Multimodal tumor therapy based on photothermal nanomaterials is a new technology to realize tumor cell thermal ablation through near-infrared light irradiation with a specific wavelength, which has the advantages of high efficiency, less adverse reactions, and effective inhibition of tumor metastasis compared with traditional treatment methods such as surgical resection, chemotherapy, and radiotherapy. Photothermal nanomaterials have gained increasing interest due to their potential applications, remarkable properties, and advantages for tumor therapy. In this review, recent advances and the common applications of photothermal nanomaterials in multimodal tumor therapy are summarized, with a focus on the different types of photothermal nanomaterials and their application in multimodal tumor therapy. Moreover, the challenges and future applications have also been speculated.Entities:
Keywords: multimodal therapy; nanomaterial; photothermal agents; photothermal therapy; synergistic effect; tumor
Year: 2022 PMID: 35898892 PMCID: PMC9309268 DOI: 10.3389/fonc.2022.939365
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Summary of photothermal nanomaterials in this review.
| PTAs | Nanomaterials | Wavelength | PCE | Applications | Reference |
|---|---|---|---|---|---|
| Inorganic photothermal nanomaterials | aAuYSs | 808nm | - | PTT+CT | ( |
| BSA-Silver NPs | 690nm | – | PTT | ( | |
| Pd nanosheets | 808nm | - | PTT | ( | |
| DPCN | 808nm | – | PTT+CT | ( | |
| USPIO-PEG-sLex | 808nm | - | PTT | ( | |
| FA-BSA-PEG/MoOx@DTX | 808nm | 43.41% | PTT+CT | ( | |
| WO3 nanosheets | 808nm | 41.6% | PTT | ( | |
| Z@CD/P | 808nm | – | PTT+CT | ( | |
| mBMNI NPs | 808nm | 45.9% | PTT+PDT+CDT | ( | |
| NB/CuS@PCM NPs | 1060nm | – | PTT+CDT | ( | |
| MoS2@DOX/MnO2-PEG | 808nm | 33.7% | PTT+CT | ( | |
| TiS2 nanosheets | 808nm | 46.82% (808nm) | PTT+IT | ( | |
| HMC-SS-PDA@CDs | 808nm | 35.9% | PTT+CT | ( | |
| CdTeSe/ZnS@QDs | 457nm | 11% | PTT+PDT | ( | |
| CNTs-PS/siRNA | 808nm | 59.3% (SCNT-PS) | PTT+GT | ( | |
| HPP | 1064nm | 45.1% | PTT | ( | |
| mGOG | 808nm | - | PTT+CT | ( | |
| DOX-Fe3O4@CGA | 808nm | – | PTT+CT | ( | |
| Nb2C@PDA-R837@RBC NPs | 1064nm | 27.6% | PTT+IT | ( | |
| BP NS-PAMAM@DOX-HA | 808nm | – | PTT+CT | ( | |
| Co-P@mSio2@DOX-MnO2 | 808nm | - | PTT+CT | ( | |
| UCNPs@mSiO2FePc-MC540 | 808nm | PTT+PDT | ( | ||
| PCM+PTX@mPBs/PEG | 808nm | 16,9% | PTT+CT | ( | |
| Organic photothermal nanomaterials | Cy5.5&ICG@ZIF-8-Dex | 780nm | 27.9% | PTT | ( |
| PPor NPs | 808nm | 70% | PTT+IT | ( | |
| T-MPs | 808nm | 16.8% | PTT+Operation | ( | |
| BBDP | 690nm | 54.2% | PTT+PDT | ( | |
| DTPADPP/TPADDPP | 635nm | 48.1% (DTPADPP) | PTT | ( | |
| CMC/CS@PPy+5Fu NPs | 808nm | 21.6% | PTT+CT | ( | |
| PANITG | 808nm | 55% | PTT+Starvation therapy | ( | |
| NIRb14 NPs | 808nm | 31.2% | PTT | ( | |
| MNP@PEDOT : PSS NPs | 808nm | – | PTT | ( | |
| Cu-PDA-FA NPs | 808nm | 46.84% | PTT+CDT+IT | ( | |
| OMCNs | 808nm | 37.3% | PTT | ( | |
| MNPs | 808nm | 87.65% | PTT+PDT | ( | |
| Organic–inorganic hybrid photothermal | Fe2O3@PEDOT-siRNA NPs | 808nm | 54.3% | PTT+GT | ( |
| RCDS@MIL-100 | 660nm | 31.2% | PTT+CDT | ( |
PCE, photothermal conversion efficiency; PTT, photothermal therapy; CT, chemotherapy; CDT, chemodynamic therapy; IT, immunotherapy; GT, gene therapy.
Figure 1Schematic diagram of PTT (using animal experimental research as a model) (34). Reproduced with permission from Liu et al., 2021.
Figure 2The schematic illustration of the multi-strategy for cancer treatment. (A) The preparation route of the FA-BSA-PEG/MoOx@DTX nanosheet and the in vitro antitumor and degradation experimental design; (B) the elucidation of the mechanism of FA-BSA-PEG/MoOx@DTX + NIR combination therapy for meliorating tumor immunosuppression, inhibiting distant tumor and lung metastasis (35). Reproduced with permission from (35).
Figure 3Schematic illustration of synthetic procedure for MnO2-SPs nanosheets and their specific functions for tumor theranostics with TME sensitivity, including the acidic/reducing condition-triggered T1-weighted MR imaging and efficient PTT against tumor (126). Reproduced with permission from (126).
Figure 4MAX phases Mn+1AXn forming elements (171). Reproduced with permission from (171).
Figure 5Schematic illustration of Cu–PDA–FA NP synthesis and Cu–PDA–FA NP-mediated PTT/CDT synergistic effect and antitumor immune activation (62). Reproduced with permission from Xu et al., 2022 (62).
Figure 6Applications of photothermal nanomaterials in tumor dual-mode therapy (left) and applications of photothermal nanomaterials in tumor multimode therapy (right).
Figure 7Schematic illustration of synthetic process and therapeutic mechanism of CFNs (317). Reproduced with permission from Liu et al., 2018.